Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers

British Journal of Cancer

Volumn 94, Issue 1, 2006, Pages 128-135

  Went, P ^a   Vasei, M ^b   Bubendorf, L ^a   Terracciano, L ^a   Tornillo, L ^a   Riede, U ^c   Kononen, J ^d   Simon, R ^e   Sauter, G ^e   Baeuerle, P A ^f  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Diomeda Life Sciences Inc   (United States)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f MICROMET AG   (Germany)

Author keywords

Colon cancer; Ep CAM; Lung cancer; Monoclonal antibody; Prostate cancer; Stomach cancer

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COLON CANCER; COLON CARCINOMA; CORRELATION ANALYSIS; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STAINING; STATISTICAL SIGNIFICANCE; STOMACH CANCER; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 30644472381     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602924     Document Type: Article

References (65)

1. Abdullah N, Greenman J, Pimenidou A, Topping KP, Monson JR (1999) The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells. Cancer Immunol Immunother 48: 517-524
2. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter G (2004) Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64: 8534-8540
3. Balzar M, Winter MJ, de Boer CJ, Litvinov SV (1999) The biology of the 17-1A antigen (Ep-CAM). J Mol Med 77: 699-712
4. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I, Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA (2005) MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol; Epub ahead of print
5. Bubendorf L, Nocito A, Moch H, Sauter G (2001) Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195: 72-79
6. Cirulli V, Crisa L, Beattie GM, Mally MI, Lopez AD, Fannon A, Ptasznik A, Inverardi L, Ricordi C, Deerinck T, Ellisman M, Reisfeld RA, Hayek A (1998) KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J Cell Biol 140: 1519-1534
7. de Bono JS, Tolcher AW, Forero A, Vanhove GF, Takimoto C, Bauer RJ, Hammond LA, Patnaik A, White ML, Shen S, Khazaeli MB, Rowinsky EK, LoBuglio AF (2004) ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res 10: 7555-7565
8. Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, Pluckthun A, Stahel RA, Zangemeister-Wittke U (2003) A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 9: 2837-2848
9. Fields AF, Keller AM, Schwartzberg L, Bernard S, Pazdur R, Kardinal C, Cohen A, Schultz J, Eisenberg P, Barber L, Edmundson S, Wisse P (2002) Edrecolomab (17-1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised North American Phase III Study. J Clin Oncol 20: A508
10. Flieger D, Hoff AS, Sauerbruch T, Schmidt-Wolf IG (2001) Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression. Clin Exp Immunol 123: 9-14
11. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G (2000) Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 356: 1981-1982
12. Gires O, Kieu C, Fix P, Schmitt B, Munz M, Wollenberg B, Zeidler R (2001) Tumor necrosis factor alpha negatively regulates the expression of the carcinoma-associated antigen epithelial cell adhesion molecule. Cancer 92: 620-628
13. Gires O, Pockl S, Chapman RD, Munz M (2004) Targeted gene expression using a 1.1 kilobase promoter fragment of the tumour-associated antigen EpCAM. Anticancer Res 24: 3715-3721
14. Haisma HJ, Pinedo HM, Rijswijk A, der Meulen-Muileman I, Sosnowski BA, Ying W, Beusechem VW, Tillman BW, Gerritsen WR, Curiel DT (1999) Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Therapy 6: 1469-1474
15. Hartung G, Hofheinz RD, Dencausse Y, Sturm J, Kopp-Schneider A, Dietrich G, Fackler-Schwalbe I, Bornbusch D, Gonnermann M, Wojatschek C, Lindemann W, Eschenburg H, Jost K, Edler L, Hochhaus A, Queisser W (2005) Adjuvant therapy with edrecolomab vs observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie 28: 347-350
16. Herlyn M, Steplewski Z, Herlyn D, Koprowski H (1979) Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76: 1438-1452
17. Himmler G, Loibner H, Schuster M, Janzek E, Stranner S, Samonigg H (2003) Murine monoclonal antibody 17-1A used as vaccine antigen (IGN101): direct induction of anti-EpCAM antibodies by vaccination of cancer patients. Proc Am Soc Clin Oncol 22: A732
18. Himmler G, Settaf A, Groiss F, Eller N, Salzberg M, Kundi M, Eckert H, Loibner H, Samonigg H (2005) A randomized placebo-controlled phase-II-study with the cancer vaccine IGN101 in patients with epithelial cancers. J Clin Oncol 23: A2555
19. Houba PH, Boven E, van der Meulen-Muileman IH, Leenders RG, Scheeren JW, Pinedo HM, Haisma HJ (2001) Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate. Int J Cancer 91: 550-554
20. Jordinson M, El-Hariry I, Calnan D, Calam J, Pignatelli M (1999) Vicia faba agglutinin, the lectin present in broad beans, stimulates differentiation of undifferentiated colon cancer cells. Gut 44: 709-714
21. Kiemer AK, Takeuchi K, Quinlan MP (2001) Identification of genes involoved in epithelial-mesenchymal transition and tumor progression. Oncogene 20: 6679-6688
22. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Figlin RA, Horvath S, Belldegrun AS (2004) Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10: 5464-5471
23. Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC (2003) Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9: 4782-4791
24. Litvinov SV, Balzar M, Winter MJ, Bakker HA, Briaire-de Bruijn IH, Prins F, Fleuren GJ, Warnaar SO (1997) Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 139: 1337-1348
25. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO (1994) Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125: 437-446
26. Martin IG, Cutts SG, Birbeck K, Gray S, Quirke P (1999) Expression of the 17-1A antigen in gastric and gastro-oesophageal junction adenocarcinomas: a potential immunotherapeutic target? J Clin Pathol 52: 701-704
27. McLaughlin PM, Harmsen MC, Dokter WH, Kroesen BJ, van der Molen H, Brinker MG, Hollema H, Ruiters MH, Buys CH, de Leij LF (2001) The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res 61: 4105-4111
28. Mellstedt H, Fagerberg J, Frodin JE, Hjelm-Skog AL, Liljefors M, Markovic K, Mosolits S, Ragnhammar P (2000) Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma. Ann NY Acad Sci 910: 254-261
29. Moldenhauer G, Momburg F, Moller P, Schwartz R, Hammerling GJ (1987) Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br J Cancer 56: 714-721
30. Mosolits S, Markovic K, Fagerberg J, Frodin JE, Rezvany MR, Kiaii S, Mellstedt H, Jeddi-Tehrani M (2005) T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody. Cancer Immunol Immunother 54: 557-570
31. Mosolits S, Markovic K, Frodin JE, Virving L, Magnusson CG, Steinitz M, Fagerberg J, Mellstedt H (2004) Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin Cancer Res 10: 5391-5402
32. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O (2004) The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23: 5748-5758
33. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmuller G, Baeuerle PA, Dreier T (2002) In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 100: 101-110
34. Neidhart J, Allen KO, Barlow DL, Carpenter M, Shaw DR, Triozzi PL, Conry RM (2004) Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine 22: 773-780
35. Oosterhoff D, Overmeer RM, de Graaf M, van der Meulen IH, Giaccone G, van Beusechem VW, Haisma HJ, Pinedo HM, Gerritsen WR (2005) Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. Br J Cancer 92: 882-887
36. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ, Gillanders WE (2004) EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64: 5818-5824
37. Peinado H, Portillo F, Cano A (2004) Transcritional regulation of cadherins during development and carcinomgenesis. Int J Dev Biol 48: 365-375
38. Peters M, Dasilva A, Weckermann D, Oberneder R, Ebner B, Kirchinger P, Fetter A, Köhne-Volland R, Baeuerle PPG (2004) Phase I study of the novel fully human monoclonal antibody MT201, directed against epithelial cellular adhesion molecule (Ep-CAM), in patients with hormone-refractory prostate cancer (HRPC). J Clin Oncol 22: A2600
39. Piyathilake CJ, Frost AR, Weiss H, Manne U, Heimburger DC, Grizzle WE (2000) The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung. Hum Pathol 31: 482-487
40. Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick DG, Grizzle WE (1999) Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 162: 1462-1466
41. Prang N, Preithner S, Brischwein K, Goster P, Woppel A, Muller J, Steiger C, Peters M, Baeuerle PA, da Silva AJ (2005) Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer 92: 342-349
42. Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones D, Dethling J, Colman J, Coward L, MacGregor S (2002) Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 360: 671-677
43. Quak JJ, Van Dongen G, Brakkee JG, Hayashida DJ, Balm AJ, Snow GB, Meijer CJ (1990) Production of a monoclonal antibody (K 931) to a squamous cell carcinoma associated antigen identified as the 17-1A antigen. Hybridoma 9: 377-387
44. Quenneville J, Fitsialos D, Rasamoelisolo M, Cross M, Glover N, MacDonald G (2005) A phase I open-label study to evaluate safety, tolerability and pharmacokinetic (PK) profile of VB4-845, an anti-EpCAM immunotoxin, in subjects with SCCHN. J Clin Oncol 23: A5539
45. Ren-Heidenreich L, Davol PA, Kouttab NM, Elfenbein GJ, Lum LG (2004) Redirected T-cell cytotoxicity to epithelial cell adhesion molecule- overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model. Cancer 100: 1095-1103
46. Riethmuller G, Gruber R, Schneider-Gädicke E, Schlimok G, Witte J, Raab R, Pichlmayer R, Pichlmaier H, Schmiegel W, Buggisch P, Höffken K, Hirche H, German Cancer Aid 17-1A Study Group (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343: 1177-1183
47. Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S, Wimberger P, Kimmig R, Baeuerle PA (2005a) Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 65: 2882-2889
48. Schlereth B, Kleindienst P, Fichtner I, Lorenczewski G, Brischwein K, Lippold S, Silva AD, Locher M, Kischel R, Lutterbuse R, Kufer P, Baeuerle PA (2005b) Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3. Cancer Immunol Immunother 27: 1-12
49. Sears HF, Herlyn D, Herlyn M, Steplewski Z, Grotzinger P, Koprowski H (1982) Ex vivo perfusion of human colon with monoclonal anticolorectal cancer antibodies. Cancer 49: 1231-1235
50. Sears HF, Herlyn D, Steplewski Z, Koprowski H (1984) Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Mod 3: 138-150
51. Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MH, Han KR, Correa AJ, Eeva M, Tze S, Belldegrun AS, Figlin RA (2004) Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 10: 2659-2669
52. Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, Sauter G (2003) HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 107: 764-772
53. Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, van Krieken JH (2005) Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 92: 1767-1772
54. Spizzo G, Obrist P, Ensinger C, Theurl I, Dunser M, Ramoni A, Gunsilius E, Eibl G, Mikuz G, Gastl G (2002) Prognostic significance of Ep-CAM and Her-2/neu overexpression in invasive breast cancer. Int J Cancer 98: 883-888
55. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R, Stopatschinskaya S, Kochli OR, Haas P, Mross F, Zuber M, Dietrich H, Bischoff S, Mirlacher M, Sauter G, Gastl G (2004) High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 86: 207-213
56. Stroehlein MA, Lordick F, Ruettinger D, Gruetzner U, Menzel H, Bartelheim K, Jaeger M, Lindhofer H, Jauch K, Peschel C, Heiss MM (2005) Treatment of peritoneal carcinomatosis due to GI-tract cancer by intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3): results of a phase I/II trial. J Clin Oncol 23: A2529
57. Sulzer M, Leers M, van NJ, Bollen E, Theunissen P (1998) Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med 157: 1319-1323
58. Thurmond LM, Stimmel JB, Ingram AC, Ryan CH, Murray DM, Eberwein DJ, Witherspoon SM, Knick VC (2003) Adenocarcinoma cells exposed in vitro to Navelbine or Taxol increase Ep-CAM expression through a novel mechanism. Cancer Immunol Immunother 52: 429-437
59. Varga M, Obrist P, Schneeberger S, Muhlmann G, Felgel-Farnholz C, Fong D, Zitt M, Brunhuber T, Schafer G, Gastl G, Spizzo G (2004) Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 10: 3131-3136
60. Went P, Dirnhofer S, Salvisberg T, Amin MB, Lim SD, Diener PA, Moch H (2005) Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. Am J Surg Pathol 29: 83-88
61. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35: 122-128
62. Winter MJ, Nagtegaal ID, van Krieken JH, Litvinov SV (2003) The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 163: 2139-2148
63. Zaloudik J, Li W, Jacob L, Kieny MP, Somasundaram R, Acres B, Song H, Zhang T, Li J, Herlyn D (2002) Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice. Cancer Gene Ther 9: 382-389
64. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin H, Mihatsch M, Gasser T, Bubendorf L (2005) Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 113: 619-628
65. Zimmermann S, Wels W, Froesch BA, Gerstmayer B, Stahel RA, Zangemeister-Wittke U (1997) A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer. Cancer Immunol Immunother 44: 1-9